Overview

This trial is active, not recruiting.

Condition chronic kidney disease
Sponsor Taipei Medical University WanFang Hospital
Start date May 2011
End date May 2014
Trial size 700 participants
Trial identifier NCT01452360, 100009

Summary

This project expects the integrated database of terminally renal ill patients combines clinical and files of Health Insurance and renal medical society database. It will provide valuable actual evidence data to quality monitoring of dialysis treatment and related academic research. Besides, using the cohort study of chronic renal disease --「epidemiologic research of chronic renal disease」, we can trace the patient continually and analysis different risk factors of chronic renal disease in Taiwan. Taken together, the results of this project --1.1「Integrate the current database of renal disease and establishment of national monitor system」and 1.2「Epidemiologic study in chronic renal disease」-- will provide the basic rules of prevention and treatment, basic research and clinic application in chronic renal disease.

United States No locations recruiting
Other Countries No locations recruiting

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: 1. Collection of CKD patient group: The patients who will select into this plan are chosen from the hospital (This hospital is defined as the renal disease improving institute) in Taiwan. New case in this hospital will be collected into the CKD patient group. In order to separate those patients into five stages of CKD, we are going to calculate the glomerular filtration rate (GFR) by using the formula of GFR. Stage I -- Renal function is normally and protein was detectable slightly in urine (GFR:≧90ml/min/1.73M2). Stage II -- Slight renal function failure was observed (GFR:60~89ml/min/1.73M2). Stage III -- Moderate renal function failure (GFR:30~59ml/min/1.73M2). Stage IV -- Severe renal function failure (GFR:15~29ml/min/1.73M2). Stage V -- End stage renal disease (GFR:<15ml/min/1.73M2). The age is from fourteen to eighty-five and whatever they are male or female will be taken into this project. 2. Collection of CKD high-risk group: The CKD patient's relative will be considerately incorporated into the CKD high-risk group. If CKD patient being confirmed, their relative who had chronic disease including DM, hypertension and CVD will be chosen into CKD high-risk group. The age is from fourteen to eighty-five and whatever they are male or female. This plan will select five thousand people into CKD high-risk group. 3. Collection of healthy control group: According to the characteristic of CKD patient group, we will select the health control group carefully (paired selection of CKD patient group, 1:1). The rules of paired selection : 1. Sex 2.Age ± 5 years 3.Location -- CKD patient and health people are get from the same hospital. Health people who had no any chronic disease and required a physical checkup which get from the hospital (This hospital should be qualified to the renal disease improving institute) will be chosen into this project. Fifteen hundred people will be taken in this plan. Exclusion Criteria: - This plan divide into three groups:1. CKD patient group -- CKD patient group have no exclusion criteria. 2. CKD high-risk group -- CKD high-risk group exclude the patient who had renal disease. 3. Heath control group -- Heath control group exclude the patient who had any chronic disease. Test of liver residual function will exclude the patient who had allergic reactions to galactose. It will exclude the person including galactosemia patient, DM patient, pregnant woman, children and disabled people.

Additional Information

Official title A Research Proposal to Set up an Integrated National Data Bank and Monitoring System and to Establish the Indicators and Risk Factors for Chronic Kidney Disease
Principal investigator Yung-Ho Hsu
Description The main source of patient in this study sub-plan 1.2 will collect the patient from medical center in Taiwan. We assume collect 7 groups in study period -- First:【CKD stage I】. Second:【CKD stage II】. Third:【CKD stage III】. Forth:【CKD stage IV】. Fifth:【CKD stage V】. Sixth:【CKD high-risk group】. Seventh:【health control group】to study case report;Total collect 11500 people. At the same time, we collect the sample of blood and urine and personal health survey to provide the basic data base for each patient.
Trial information was received from ClinicalTrials.gov and was last updated in October 2011.
Information provided to ClinicalTrials.gov by Taipei Medical University WanFang Hospital.